Growing strategic initiatives associated with the point-of-care testing for women health are driving the growth of the Point-of-Care Testing for Women Health Market at a CAGR of 6.26% during the forecast period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Point-of-Care Testing for Women Health Market” that contains the information from 2019 to 2035.

The Global Point-of-Care Testing for Women Health Market is estimated to register a CAGR of 6.26 % during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Point-of-Care Testing for Women Health Market — Swiss Precision Diagnostics GmbH- Clearblue, Wondfo, Church & Dwight Co., Inc.-First Response, Hangzhou Singclean Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, INNOVITA Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., Chungdo Pharm Co., Ltd., and others.

The Global Point-of-Care Testing for Women Health Market accounted for registering a CAGR of 6.26% during the forecast period and is estimated to reach USD 33.74 billion by 2035.

The high prevalence of infectious diseases among women is significantly fueling the growth of the global point-of-care (POC) testing market for women’s health by driving demand for rapid and accessible diagnostic solutions. Conditions such as sexually transmitted infections (STIs), urinary tract infections (UTIs), and HPV require timely detection for effective treatment and management, making POC tests highly valuable due to their ability to deliver quick results and facilitate early intervention. For instance, as per the Cleveland Clinic stated that up to 75% of women or individuals assigned female at birth (AFAB) will experience at least one vaginal yeast infection during their lifetime, with more than half encountering two or more infections. Yeast infections rank as the second most frequent cause of vaginitis, after bacterial vaginosis, which is the most common. Further, World Health Organization reported, in 2022, it was estimated that 1.1 million pregnant women were infected with syphilis, leading to more than 390,000 adverse birth outcomes. 

Sexually transmitted infections like gonorrhea and chlamydia are primary contributors to pelvic inflammatory disease and infertility in women. Moreover, in December 2022, Office on Women’s Health reported that each year, over 9 million women in the United States are diagnosed with a sexually transmitted infection (STI). Women frequently experience more severe health issues from STIs compared to men, including infertility. Also, as per the Centers for Disease Control and Prevention, there were approximately 256,299 cases of Gonorrhea among women in 2022 in the US. This demand is further amplified by the increasing awareness of these infections, the convenience of at-home and immediate testing, and supportive healthcare policies promoting regular screening. Technological advancements that enhance test accuracy and ease of use also contribute to the growing adoption of POC testing, addressing the need for effective and efficient monitoring and management of infectious diseases in women.

Access Full Report @ https://www.marketresearchfuture.com/reports/point-of-care-testing-women-health-market-59926

Segmental Analysis

The Global Point-of-Care Testing for Women Health Market has been segmented based on by Product, by Age, by Sample Type, by Test Type, by Technology, by Application, by Distribution Channel, and by End User.

Based on Product, this segment includes Instruments/Devices, Reagents & Kits, Consumables. The Reagents & Kits segment dominated the global market in 2024, while the Instruments/Devices segment is projected to be the fastest–growing segment during the forecast period. Reagents and kits refer to specialized diagnostic tools designed for on-site, rapid testing outside of traditional laboratory settings. Reagents are chemical substances or compounds used in tests to detect, measure, or analyze specific biomarkers related to women's health conditions, such as pregnancy, hormonal levels, or infectious diseases. Kits encompass a complete set of components, including reagents, testing devices, and instructions, that facilitate the user-friendly and accurate performance of tests. These reagents and kits are essential for enabling timely and effective health monitoring, empowering both healthcare providers and individuals with the ability to perform tests quickly and conveniently in various settings.

Based on Age, this segment includes Adolescent, Adult, Geriatric. The Adult segment dominated the global market in 2024, while the Adolescent segment is projected to be the fastest–growing segment during the forecast period. The increasing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and cancer among adult women is driving demand for timely and accessible diagnostic testing. For instance, according to womenshealth.gov, In 2022, Approximately 1 in 9 adult women in the United States, or 15 million women, have diabetes. Moreover, according to World Health Organization In 157 out of 185 nations, breast cancer was the most frequent cancer among women in 2022. The disease is directly responsible for 1.5 million fatalities annually. Additionally, the growing emphasis on personalized and preventive healthcare solutions is enhancing the adoption of POCT, which offers rapid and accurate results.

Based on Sample Test, this segment includes Serum, Plasma, Whole Blood, Urine, Others. The Whole Blood segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. The use of whole blood as a sample type is driven by several key factors. The convenience and simplicity of whole blood collection streamline the testing process, making it ideal for rapid and efficient diagnostics in diverse settings, from clinics to home environments. Whole blood tests are versatile, applicable to a broad range of health markers such as glucose levels, cholesterol, and infectious disease indicators, thereby supporting comprehensive women's health monitoring. The growing emphasis on routine health monitoring and early disease detection, coupled with increasing patient preference for quick and minimally invasive tests, further drives the adoption of whole blood-based POCT solutions.

Based on Test Type, this segment includes Testosterone Test, Estradiol Test, Anti-Müllerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-stimulating Hormone Test, Luteinizing Hormone Test, β-hCG Test, Others. The β-hCG Test segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. β-hCG Test is a diagnostic test that measures the concentration of beta-human chorionic gonadotropin (β-hCG) in the blood or urine. This hormone is an early marker of pregnancy and is used to confirm pregnancy, monitor pregnancy progression, and diagnose certain medical conditions. β-hCG is produced by the placenta shortly after implantation, making it a reliable marker for detecting pregnancy.

Based on Technology, this segment includes Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others. The Fluorescence Immunoassays segment dominated the global market in 2024, while the Lab-on-a-Chip segment is projected to be the fastest–growing segment during the forecast period. Fluorescence Immunoassays are a sophisticated diagnostic technology that leverages the principles of fluorescence to detect and quantify specific biomolecules through antigen-antibody interactions. This technology is widely used in clinical diagnostics, research, and various applications requiring precise and sensitive detection of target analytes. Fluorescence immunoassays utilize fluorescent labels to provide a visual signal that indicates the presence of a specific target molecule. The basic principle involves the use of fluorescent dyes or proteins that emit light when excited by a specific wavelength. This fluorescence is detected and measured to determine the quantity of the target analyte in the sample.

Based on Application, this segment includes Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections (Chlamydia, Gonorrhea, HIV, Syphilis, Others), Fertility Conditions (Polycystic Ovary Syndrome, Ovulation Disorders, Others), Pregnancy Testing, Others. The Pregnancy Testing segment dominated the global market in 2024, while the Fertility Conditions segment is projected to be the fastest–growing segment during the forecast period. This growth is driven by a rising prevalence of infertility issues, such as polycystic ovary syndrome (PCOS) and ovulation disorders, along with increasing age of first-time pregnancies and growing awareness about reproductive health. Advances in diagnostic tools and increased access to fertility treatments are further accelerating demand in this segment.

Based on Distribution Channel, this segment includes Offline (Hospital Pharmacies, Retail Pharmacies, Hypermarket/Supermarket) and Online (E-commerce Platforms and Online Pharmacies). The Offline segment dominated the global market in 2024, while the Online segment is projected to be the fastest–growing segment during the forecast period. The established relationships between manufacturers and traditional distribution networks, such as medical device distributors, wholesalers, and specialty suppliers, which facilitate streamlined procurement and inventory management. Offline channels benefit from the tangible presence and direct interaction between sales representatives and healthcare providers, enabling personalized demonstrations, hands-on training, and immediate support.

Based on End-User, this segment includes Hospitals, Diagnostic Laboratories, Home Settings, Others. The Home Settings segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. In home settings, Point-of-Care Testing (POCT) for women’s health is gaining traction due to its alignment with the growing demand for accessible and convenient health management solutions. The adoption of POCT in home environments is driven by the need for immediate, reliable diagnostic tools that empower individuals to monitor their health proactively, without the necessity of frequent clinic visits. These devices, which include tests for pregnancy, ovulation, and urinary tract infections, provide rapid and accurate results, facilitating timely and informed health decisions. The ease of use inherent in home POCT devices minimizes the need for specialized training, broadening their appeal and usability across diverse demographics. Additionally, the ability to perform tests at home significantly reduces healthcare costs and alleviates pressure on healthcare systems by diminishing the need for in-person consultations.

Regional Analysis

Geographically, the Global Point-of-Care Testing for Women Health Market has been segmented into North America, Europe, Asia-Pacific and Rest of the World.

Major demand factors driving the North America market are the high prevalence of infectious diseases in women and increasing cases of infertility among women and growing strategic initiatives associated with the point-of-care testing for women health. The North America Point-of-Care (POC) Testing for Women's Health market is experiencing significant growth, driven by increasing demand for rapid diagnostic tools, especially for pregnancy, fertility, and sexually transmitted infections. Advancements in POC technology, including portable and easy-to-use devices, are enhancing accessibility and convenience, making them popular in both clinical and home settings. In January 2021, Ovry, a Canadian start-up focused on reducing pregnancy-related stress for women, sells extremely thin pregnancy and ovulation test strips in boxes of four or eighteen strips. In addition, the company offers the product in discreet packaging and at a significantly lower cost than other pregnancy tests on the market.

The Europe Point-of-Care Testing (POCT) market for women's health is undergoing substantial growth, driven by the increasing demand for rapid and accurate diagnostic solutions across various female health issues, including reproductive health, infectious diseases, and chronic conditions. Advances in technology have led to the development of innovative testing devices that offer quick results, enhancing patient management and reducing the need for laboratory visits. In May 2023, The CSEM Tools for Life Sciences (Switzerland) team is collaborating with MOMM Diagnostics (Switzerland) to create a cutting-edge point-of-care solution for preeclampsia diagnosis. The solution employs enzyme-linked lateral flow immunoassays (ELLFIA) with ion-sensitive electrodes in a disposable test cartridge. This integrated approach provides a point-of-care diagnostic test platform that is 50-100 times more sensitive than traditional lateral flow immunoassays. MOMM Diagnostics' comprehensive solution for rapid and reliable blood testing has enormous potential as a game changer in clinical settings.

The Asia-Pacific Point-of-Care Testing for Women's Health market is witnessing robust growth, driven by rising awareness of women's health issues, increasing demand for rapid diagnostics, and technological advancements in POCT devices. The region's growing population, coupled with a higher prevalence of chronic conditions such as diabetes, pregnancy-related complications, and infectious diseases, has fueled the need for accessible and efficient testing solutions. Asian and Pacific Islander women may be more susceptible to cardiovascular problems than other women, according to the American Heart Association, Inc. in 2021. This could lead to a rise in the need for POCT.

The Point-of-Care Testing market for women's health in the Middle East, Africa, and South America is experiencing considerable growth, driven by increasing awareness of women's health issues and the demand for rapid diagnostic solutions. In these regions, access to healthcare can be limited, making POCT an essential tool for early detection and management of conditions such as pregnancy complications, sexually transmitted infections, and reproductive health disorders. Collaborations between healthcare providers and technology firms are also pivotal in expanding the reach of POCT solutions in these underserved areas. In November 2019, Abdul Latif Jameel (Saudi Arabia) and Cellspect (Japan) have collaborated to bring the next generation of low-cost, portable point-of-care blood testing devices to developing markets.

Key Findings of the Study

• The Global Point-of-Care Testing for Women Health Market is expected to reach USD 33.74 billion by 2035, at a CAGR of 6.26% during the forecast period.


• The North America region accounted for the fastest-growing global market.


• Based on the Application, the Pregnancy Testing segment was attributed to holding the largest market in 2024.


• Swiss Precision Diagnostics GmbH- Clearblue, Wondfo, Church & Dwight Co., Inc.-First Response, Hangzhou Singclean Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, INNOVITA Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., Chungdo Pharm Co., Ltd., and others are some of the players in the market.